Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting.

Journal: African health sciences
PMID: 35283956

Abstract

BACKGROUND: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (E/C/F/TDF) in treatment-naïve and experienced patients with HIV infection was demonstrated in phase 3 trials. The primary objective of this study was to evaluate effectiveness and safety of E/C/F/TDF in real world settings.

Authors

  • Bilgul Mete
    Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine Department of Infectious Diseases and Clinical Microbiology.
  • Alper Gunduz
    Sisli Hamidiye Etfal Research and Training Hospital Department of Infectious Diseases and Clinical Microbiology.
  • Hayat Kumbasar Karaosmanoglu
    Bakirkoy Dr Sadi Konuk Research and Training Hospital, Department of Infectious Diseases and Clinical Microbiology.
  • Fatma Gumuser
    Goztepe Medeniyet University, Medical School Department of Infectious Diseases and Clinical Microbiology.
  • Sibel Bolukcu
    Bezm-i Alem University, Vakif Gureba Hospital, Department of Infectious Diseases and Clinical Microbiology.
  • Dilek Sevgi Yildiz
    Sisli Hamidiye Etfal Research and Training Hospital Department of Infectious Diseases and Clinical Microbiology.
  • Ozlem Altuntas Aydin
    Bakirkoy Dr Sadi Konuk Research and Training Hospital, Department of Infectious Diseases and Clinical Microbiology.
  • Bilgenur Bilge
    Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine Department of Medical Genetics All authors meet the ICMJE authorship criteria.
  • Ilyas Dokmetas
    Sisli Hamidiye Etfal Research and Training Hospital Department of Infectious Diseases and Clinical Microbiology.
  • Fehmi Tabak
    Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine Department of Infectious Diseases and Clinical Microbiology.

Keywords

External Resources

Popular Topics
Recent Journals